Molecular basis of antithrombin deficiency in four Japanese patients with antithrombin gene abnormalities including

Mayu Kyotani1, Kaoru Okumura, Akira Takagi

  • 1Department of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Insights

Four distinct antithrombin (AT) gene mutations were identified in Japanese patients with AT deficiency. Different mutations impact AT secretion, heparin binding, and cofactor activity, leading to distinct deficiency types.

Area of Science:

  • Genetics
  • Molecular Biology
  • Biochemistry

Background:

  • Antithrombin (AT) deficiency is a genetic disorder predisposing individuals to thrombosis.
  • Understanding the molecular basis of AT deficiency is crucial for risk assessment and management.

Observation:

  • Four distinct heterozygous mutations in the AT gene were identified in four unrelated Japanese patients.
  • Two novel mutations (2417delT [FS-3Stop] and C2640T [Ala59Val]) and two previously reported mutations (T5342C [Ser116Pro] and T72C [Met-32Thr]) were found.

Findings:

  • In vitro expression revealed that FS-3Stop-AT and Met-32Thr-AT were not secreted, while Ser116Pro-AT and Ala59Val-AT were secreted normally.
  • Ser116Pro mutation impaired heparin binding and reduced cofactor activity.
  • Ala59Val mutation showed normal heparin binding but severely reduced cofactor activity.

Implications:

  • FS-3Stop and Met-32Thr mutations are associated with Type I AT deficiency (impaired secretion).
  • Ser116Pro and Ala59Val mutations are associated with Type II AT deficiency (impaired function).
  • These findings highlight diverse molecular mechanisms underlying AT deficiency due to specific AT gene abnormalities.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life